| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.32 | 2e-06 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.23 | 6e-06 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-05 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.21 | 1e-05 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-05 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | -0.2 | 5e-05 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-05 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.18 | 5e-05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.3 | 6e-05 |